scispace - formally typeset
Search or ask a question
Author

Samina Sabir

Bio: Samina Sabir is an academic researcher from Government College University, Faisalabad. The author has an hindex of 1, co-authored 1 publications receiving 1 citations.

Papers
More filters
Book ChapterDOI
01 Jan 2021
TL;DR: Wang et al. as mentioned in this paper proposed to use traditional Chinese medicine (TCM) against SARS-CoV in the third edition of COVID-19 Treatment Guidelines (2020) published in January 2019.
Abstract: Keeping in view the pandemic situation and whose recommendations to search antiviral medicines, biologists, pathologists, and microbiologists started working on that Chinese government has recommended therapeutic application of traditional Chinese medicine (TCM) against COVID-19 in the third edition of COVID-19 Treatment Guidelines (2020) published in January From the day onward, hundreds of herbs have been practiced all over China This chapter has been planned to compile existing information for future utilization of TCM all over the world with better understanding and minimal chances of side effects For well understanding of TCM as reliable treatment (for COVID-19), it is aimed to pool data of TCM from its history of usage against other viruses and against related viruses of SARS-CoV, collection of the data regarding case studies with positive outcomes, detailed pool of knowledge about most practiced (approved/proposed) decoctions, frequently used components of these decoctions, their active ingredients, possible mechanism to inhibit viruses, similarity of SARS-CoV with SARS-CoV-2, and possibility to treat COVID-19 with antiviral drugs previously used against SARS-CoV Additional relevant meta-analyses have been reviewed that may guide about practical implementation of these TCM in the future round the globe

3 citations


Cited by
More filters
12 May 2020
TL;DR: The compounds in Shufeng Jiedu Capsule can regulate the signaling pathway of human cytomegalov virus infection, Kaposi's sarcoma associated herpesvirus infection, IL-17 signaling pathway, small cell lung cancer, etc. to treat COVID-19 by binding with SARS-CoV-2 3CL hydrolase and ACE2.
Abstract: Objective: To explore the novel coronavirus disease 2019 (COVID-19) treatment mechanism and active ingredients of Shufeng Jiedu Capsule by network pharmacology and molecular docking. Methods: TCMSP databases were used to search the chemical composition and target of Shufeng Jiedu Capsule, which was composed of Isatidis Radix, Polygonum cuspidatum, Forsythia suspensa, Phragmitis Rhizoma, Patrinia, Verbena officinalis, Bupleurum chinense, and Glycyrrhiza uralensis. The Swiss target prediction database was used to remove the target with possibility of 0. The corresponding targets of the disease were searched in the GeneCards and OMIM databases with the key words of "coronavirus", "pneumonia", "cough", and "fever". Through the UniProt databases to correct the name of the target point, take the intersection of Shufeng Jiedu Capsule and the disease target point, then use the software of Cytoscape 3.7.2 to build the network of traditional Chinese medicine-compound-target for visualization, through DAVID databases to carry out the GO function enrichment analysis and KEGG pathway enrichment analysis, predict the interaction mechanism of the target, and draw the column and bubble chart for visualization. The novel coronavirus (SARS-CoV-2) 3CL hydrolase was then docking with all compounds and the first five compounds with the least binding energy were selected for docking with angiotensin-converting enzyme II (ACE2). Results: The traditional Chinese medicine-compound-target compound target network contains eight kinds of traditional Chinese medicine-compound-target, 157 compounds and 260 corresponding targets. The key targets were PTGS2, ESR1, AR, etc. There were 393 items in GO functional enrichment analysis (P < 0.05), and 139 signaling pathways in KEGG pathway enrichment analysis. Molecular docking results showed that SARS-CoV-2 3CL hydrolase and ACE2 binding energy of the five core compounds, including 6-(3-oxoindolin-2-ylidene) indolo [2,1-b] quinazolin-12-one, bicuculline, physciondiglucoside, dihydroverticillatine, and licoisoflavanone, was smaller than that of recommended chemical drugs, and the binding energy to ACE2 was similar to that of the recommended chemical drug. Conclusion: The compounds in Shufeng Jiedu Capsule can regulate the signaling pathway of human cytomegalovirus infection, Kaposi's sarcoma associated herpesvirus infection, IL-17 signaling pathway, small cell lung cancer, etc. to treat COVID-19 by binding with SARS-CoV-2 3CL hydrolase and ACE2.

4 citations

Proceedings ArticleDOI
16 Aug 2022
TL;DR: In this article , a leading drug candidate Cepharanthine (CEP) has shown better results and effectiveness than recently used antiviral drug candidates such as Favipiravir, IDX184, Remedesivir, Ribavirin and etc.
Abstract: Drug repurposing is an unconventional approach that is used to investigate new therapeutic aids of existing and shelved drugs. Recent advancement in technologies and the availability of the data of genomics, proteomics, transcriptomics, etc., and with the accessibility of large and reliable database resources, there are abundantly of opportunities to discover drugs by drug repurposing in an efficient manner. The recent pandemic of SARS-COV-2, that caused the death of 6,245,750 human beings to date, has tremendously increase the exceptional usage of bioinformatics tools in interpreting the molecular characterizations of viral infections. In this paper, we have employed various bioinformatics tools such as AutoDock-Vina, PyMol etc. We have found a leading drug candidate Cepharanthine (CEP) that has shown better results and effectiveness than recently used antiviral drug candidates such as Favipiravir, IDX184, Remedesivir, Ribavirin and etc. This paper has analyzed CEP’s potential therapeutic importance as a drug of choice in managing COVID-19 cases. It is anticipated that proposed study would be beneficial for researchers and medical practitioners in handling SARS-CoV-2 and its variant related diseases.
Proceedings ArticleDOI
02 Jun 2022
TL;DR: Cepharanthine potential therapeutic importance as a drug of choice in managing COVID-19 cases is analyzed and it is anticipated that proposed study would be beneficial for researchers and medical practitioners in handling SARS-CoV-2 and its variant related diseases.
Abstract: Drug repurposing is an unconventional approach that is used to investigate new therapeutic aids of existing and shelved drugs. Recent advancement in technologies and the availability of the data of genomics, proteomics, transcriptomics, etc., and with the accessibility of large and reliable database resources, there are abundantly of opportunities to discover drugs by drug repurposing in an efficient manner. The recent pandemic of SARS-COV-2, that caused the death of 6,245,750 human beings to date, has tremendously increase the exceptional usage of bioinformatics tools in interpreting the molecular characterizations of viral infections. In this paper, we have employed various bioinformatics tools such as AutoDock-Vina, PyMol etc. We have found a leading drug candidate Cepharanthine (CEP) that has shown better results and effectiveness than recently used antiviral drug candidates such as Favipiravir, IDX184, Remedesivir, Ribavirin and etc. This paper has analyzed CEP’s potential therapeutic importance as a drug of choice in managing COVID-19 cases. It is anticipated that proposed study would be beneficial for researchers and medical practitioners in handling SARS-CoV-2 and its variant related diseases.